國家衛生研究院 NHRI:Item 3990099045/10643
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 859780      線上人數 : 829
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10643


    題名: Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial
    作者: Wu, UI;Hsieh, SM;Lee, WS;Wang, NC;Kung, HC;Ou, TY;Chen, FL;Lin, TY;Chen, YC;Chang, SC
    貢獻者: Division of Infectious Diseases
    摘要: Background: We conducted a phase I/II clinical trial to evaluate the safety and immunogenicity of a Madin-Darby canine kidney (MDCK) cell-grown inactivated H7N9 influenza vaccine for pandemic preparedness purposes. Methods: Between April 7, 2015 and May 27, 2016, healthy adults aged 20-60. years were enrolled sequentially in phase I (n = 40) and phase II (n = 160) from three hospitals in Taiwan and randomized to receive 2 doses of whole-virus H7N9 vaccine (15 or 30. μg hemagglutinin antigen (HA) with or without an aluminum hydroxide adjuvant) at 21-day intervals. Safety up to 180. days and changes in hemagglutinin inhibition (HI) titers at 21. days after each vaccination were determined. Results: Of the 200 randomized subjects, 193 (96.5%) received 2 doses of the study vaccine and were included in the intention-to-treat analysis for safety, and 190 (95%) were included in the per-protocol analysis for immunogenicity. Most adverse events were mild and transient; no death or vaccine-related serious adverse events were reported. Overall, higher immune responses were observed in the groups administered with 30. μg. HA formulation than in the other two groups administered with 15. μg. HA formulation. The highest immune response was observed in subjects who received 2 doses of the adjuvanted vaccine containing 30. μg. HA with HI titer, seroprotection rate, seroconversion rate, and seroconversion factor of 36.2, 64.6%, 64.6% and 5.7, respectively. Conclusions: Our study demonstrated that the H7N9 influenza vaccine containing 30. μg. HA with aluminum hydroxide adjuvant was immunogenic and safe in adults aged 20-60. years.CLINICALTRIALS.GOV identifier: NCT02436928.
    日期: 2017-07-24
    關聯: Vaccine. 2017 Jul 24;35(33):4099-4104.
    Link to: http://dx.doi.org/10.1016/j.vaccine.2017.06.044
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0264-410X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000406735500008
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85021388685
    顯示於類別:[陳宜君] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP85021388685.pdf629KbAdobe PDF354檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋